DT News - Canada - Vivos Therapeutics announces exclusive distribution agreement with GM Instruments for the U.S. and Canada

Search Dental Tribune

Vivos Therapeutics announces exclusive distribution agreement with GM Instruments for the U.S. and Canada

Photo: Provided by www.vivos.com

Thu. 16 June 2022


Vivos Therapeutics has entered into an exclusive distribution agreement with GM Instruments for the distribution of GM Instruments’ NR6 Rhinomanometer. Vivos is a revenue-stage medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities as well as mild to moderate obstructive sleep apnea (OSA) and snoring in adults.

The agreement is the only FDA-approved 4-phase rhinomanometer available in the U.S. used to calculate nasal airway resistance by measuring nasal flow and the pressure producing that flow.

Under this new agreement, Vivos becomes the exclusive U.S. and Canadian distributor of this specialized diagnostic equipment for evaluating nasal breathing and function in dental patients with sleep and breathing issues. The objective measurement of nasal breathing can be an essential data point in determining the appropriate breathing and sleep issue treatment pathway as well as a predictor of potential Continuous Positive Airway Pressure (CPAP) intolerance or other treatment failure.

“With this new agreement, every U.S. or Canadian dentist who wishes to evaluate the breathing function of a patient will need to engage with Vivos for this diagnostic equipment. We expect this will provide Vivos an immediate new revenue stream as well as a substantial competitive advantage and opportunity to present Vivos’ proprietary oral appliance technology to a wider audience,” said Vivos Chairman and CEO, Kirk Huntsman.

Based in the United Kingdom, GM Instruments is a global manufacturer and distributor of diagnostic technology for assessing nasal and respiratory flow and function. The GM Instruments’ NR6 Rhinomanometer offers a quick non-invasive test to measure the function of the nose during active breathing. These test results are being used by Vivos-trained dentists and others to measure outcomes of improvement for pre- mid- and post-treatment of patients undergoing a variety of treatment modalities. Additionally, GM Instruments products are planned for use as part of research protocols to improve and support the outcomes of Vivos products and methods for OSA diagnosis and treatment.

The NR6 Rhinomanometer is used across the world in specialties that address nasal obstruction and nasal flow limitations. Recent studies show the impact of nasal resistance on the distribution of apneas and hypopneas in OSA. Such studies have also highlighted the use of Rhinomanometry in patient selection for probable success or failure with CPAP and oral appliance therapy. The research findings emphasize the importance of measuring nasal flow and transnasal pressure in reducing disease and improving breathing.

Dr. Martha Cortes, a Vivos-trained dentist in New York City who has used Vivos technology to treat more than 1,600 patients in her Manhattan practice, emphasized the importance of having NR6 rhinomanometry available to her patients, stating: “For the first time, I have a dynamic and objective measurement that I can take multiple times throughout treatment to measure and demonstrate the impact that Vivos therapy may have on the nasal cavity which could affect the upper airway. As I frequently remind my patients and colleagues, it is only an opinion without data.”

“Many medical problems such as OSA, overall lung function, and even spinal and posture issues are related to nasal resistance and poor breathing, and our breathing is disrupted before our sleep is disrupted.  With this strong collaboration with Vivos, we believe we have the opportunity to change the standard of care for OSA to improve patient outcomes and manage their health with better testing and assessments,” said Dr. Karen Parker Davidson, RN, vice president of sales for GM-Instruments, North America.

The clinical evaluation of breathing flow and function has recently taken center stage in the treatment of sleep apnea as research continues to forge links between breathing and sleep. With this exclusive distribution agreement for the NR6 Rhinomanometer, which is utilized by dentists worldwide, Vivos solidifies its leadership role as the first company in the global effort to identify and address sleep and breathing issues through the collaborative efforts of dental and medical professionals.

For more information, visit www.vivos.com.


To post a reply please login or register